+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

LAMEA Tuberculosis Diagnostics Market Size, Share & Trends Analysis Report By End Use (Diagnostic Laboratories, Hospitals & Clinics, and Others), By Type, By Country and Growth Forecast, 2024 - 2031

  • PDF Icon

    Report

  • 122 Pages
  • August 2024
  • Region: Africa, Middle East
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5997317
The Latin America, Middle East and Africa Tuberculosis Diagnostics Market would witness market growth of 7.0% CAGR during the forecast period (2024-2031).

The Brazil market dominated the LAMEA Tuberculosis Diagnostics Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $65.8 million by 2031. The Argentina market is showcasing a CAGR of 7.9% during (2024 - 2031). Additionally, The UAE market would register a CAGR of 6.1% during (2024 - 2031).



The market has seen significant advancements in recent years, driven by the continuous development and launch of innovative products by companies committed to combating this health challenge. In addition to improving accuracy, the speed of TB diagnostics has also been a major focus of innovation. Rapid diagnostics are essential in TB control, as they enable healthcare providers to diagnose and initiate treatment promptly, which is crucial for preventing the spread of the disease.

Furthermore, the ongoing innovation in TB diagnostics is not limited to individual products but extends to digital technology integration. Digital data management and analysis platforms are becoming increasingly common in TB diagnostics, allowing for more efficient tracking of cases and treatment outcomes. For example, digital chest X-ray systems equipped with artificial intelligence (AI) algorithms can automatically analyze images and identify signs of TB, assisting healthcare providers in making quicker and more accurate diagnoses. These systems can be particularly useful in screening large populations or settings where trained radiologists are in short supply.

In Saudi Arabia, the demand for tuberculosis diagnostics is influenced by the country’s large expatriate population and the need for effective screening and control measures in densely populated urban centers. The Kingdom has implemented stringent TB screening protocols for expatriates, including mandatory testing for those seeking work visas or residency. This has increased the demand for reliable and rapid diagnostic tools in public health facilities and private clinics. Saudi Arabia’s commitment to improving TB detection, especially in high-risk populations, has driven the adoption of advanced diagnostic methods, including molecular tests and interferon-gamma release assays (IGRAs), to ensure early and accurate diagnosis. Adopting advanced diagnostic technologies, including molecular tests, drug susceptibility testing, and digital radiography, is essential for improving TB detection rates and treatment outcomes. Therefore, as countries in the region continue to enhance their TB control efforts, the demand for effective, reliable, and accessible TB diagnostics is expected to grow, contributing to the overall expansion of the market in LAMEA.

Based on End Use, the market is segmented into Diagnostic Laboratories, Hospitals & Clinics, and Others. Based on Type, the market is segmented into Detection of Latent Infection (Skin Test & IGRA), Phage Assay, Detection of Drug Resistance (DST), Nucleic Acid Testing, Radiographic Method, Cytokine Detection Assay, Diagnostic Laboratory Methods, and Other Methods. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

List of Key Companies Profiled

  • Abbott Laboratories
  • Qiagen N.V
  • Thermo Fisher Scientific Inc.
  • Becton, Dickinson and Company
  • F.Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Danaher Corporation
  • DiaSorin S.p.A.
  • Bruker Corporation

Market Report Segmentation

By End Use
  • Diagnostic Laboratories
  • Hospitals & Clinics
  • Others
By Type
  • Detection of Latent Infection (Skin Test & IGRA)
  • Phage Assay
  • Detection of Drug Resistance (DST)
  • Nucleic Acid Testing
  • Radiographic Method
  • Cytokine Detection Assay
  • Diagnostic Laboratory Methods
  • Other Methods
By Country
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Tuberculosis Diagnostics Market, by End Use
1.4.2 LAMEA Tuberculosis Diagnostics Market, by Type
1.4.3 LAMEA Tuberculosis Diagnostics Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
3.3 Porter Five Forces Analysis
Chapter 4. LAMEA Tuberculosis Diagnostics Market by End Use
4.1 LAMEA Diagnostic Laboratories Market by Country
4.2 LAMEA Hospitals & Clinics Market by Country
4.3 LAMEA Others Market by Country
Chapter 5. LAMEA Tuberculosis Diagnostics Market by Type
5.1 LAMEA Detection of Latent Infection (Skin Test & IGRA) Market by Country
5.2 LAMEA Phage Assay Market by Country
5.3 LAMEA Detection of Drug Resistance (DST) Market by Country
5.4 LAMEA Nucleic Acid Testing Market by Country
5.5 LAMEA Radiographic Method Market by Country
5.6 LAMEA Cytokine Detection Assay Market by Country
5.7 LAMEA Diagnostic Laboratory Methods Market by Country
5.8 LAMEA Other Methods Market by Country
Chapter 6. LAMEA Tuberculosis Diagnostics Market by Country
6.1 Brazil Tuberculosis Diagnostics Market
6.1.1 Brazil Tuberculosis Diagnostics Market by End Use
6.1.2 Brazil Tuberculosis Diagnostics Market by Type
6.2 Argentina Tuberculosis Diagnostics Market
6.2.1 Argentina Tuberculosis Diagnostics Market by End Use
6.2.2 Argentina Tuberculosis Diagnostics Market by Type
6.3 UAE Tuberculosis Diagnostics Market
6.3.1 UAE Tuberculosis Diagnostics Market by End Use
6.3.2 UAE Tuberculosis Diagnostics Market by Type
6.4 Saudi Arabia Tuberculosis Diagnostics Market
6.4.1 Saudi Arabia Tuberculosis Diagnostics Market by End Use
6.4.2 Saudi Arabia Tuberculosis Diagnostics Market by Type
6.5 South Africa Tuberculosis Diagnostics Market
6.5.1 South Africa Tuberculosis Diagnostics Market by End Use
6.5.2 South Africa Tuberculosis Diagnostics Market by Type
6.6 Nigeria Tuberculosis Diagnostics Market
6.6.1 Nigeria Tuberculosis Diagnostics Market by End Use
6.6.2 Nigeria Tuberculosis Diagnostics Market by Type
6.7 Rest of LAMEA Tuberculosis Diagnostics Market
6.7.1 Rest of LAMEA Tuberculosis Diagnostics Market by End Use
6.7.2 Rest of LAMEA Tuberculosis Diagnostics Market by Type
Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 SWOT Analysis
7.2 Qiagen N.V
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Product Launches and Product Expansions:
7.2.6 SWOT Analysis
7.3 Thermo Fisher Scientific, Inc
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Product Launches and Product Expansions:
7.3.6 SWOT Analysis
7.4 Becton, Dickinson, and Company
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.4.6 SWOT Analysis
7.5 F. Hoffmann-La Roche Ltd
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Acquisition and Mergers:
7.5.6 SWOT Analysis
7.6 Hologic, Inc
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 SWOT Analysis
7.7 Danaher Corporation
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 SWOT Analysis
7.8 DiaSorin S.p.A
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expenses
7.8.5 SWOT Analysis
7.9 Bruker Corporation
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expense
7.9.5 SWOT Analysis
7.10. Revvity, Inc
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expenses
7.10.5 SWOT Analysis

Companies Mentioned

  • Abbott Laboratories
  • Qiagen N.V
  • Thermo Fisher Scientific Inc.
  • Becton, Dickinson and Company
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Danaher Corporation
  • DiaSorin S.p.A.
  • Bruker Corporation
  • Revvity, Inc.

Methodology

Loading
LOADING...